Acquired CD20 Loss as a Mechanism of Resistance to Mosunetuzumab in Relapsed Follicular Lymphoma . Mediterr J Hematol Infect Dis [Internet]. 2026 Jan. 1 [cited 2026 Jun. 9];18(1):e2026014. Available from: https://www.mjhid.org/mjhid/article/view/6199